Skip to content
Download PDF

Chronic Obstructive Pulmonary Disease

Chapter 303 | Part 7: Disorders of the Respiratory System · Part 7 – Respiratory Disorders · Chapter 303

Key Clinical Points

  1. COPD is defined by persistent respiratory symptoms and airflow obstruction (FEV1/FVC < 0.7).
  2. Airflow obstruction is the primary physiological marker; it is persistent and does not fully normalize with bronchodilators.
  3. Emphysema is an anatomical definition (alveolar destruction), while chronic bronchitis is a clinical definition (cough and phlegm).
  4. Smoking cessation is the most effective intervention to slow lung function decline.
  5. Alpha-1 antitrypsin deficiency (PiZ genotype) is a confirmed genetic risk factor for early-onset COPD.
  6. Clubbing of digits is NOT a sign of COPD; its presence requires investigation for other conditions like lung cancer.
  7. Exacerbations are associated with increased loss of lung function and higher mortality risk.
  8. PRISm (Preserved ratio–impaired spirometry) is a high-risk phenotype with normal FEV1/FVC but reduced FEV1.
  9. The BODE index is a superior predictor of mortality compared to FEV1 alone.
  10. Management goals include both symptomatic relief and risk reduction for future exacerbations.

1. DEFINITION & OVERVIEW

• Definition: Chronic obstructive pulmonary disease (COPD) is a disease state characterized by persistent respiratory symptoms and airflow obstruction. • Primary Marker: Airflow obstruction is the primary physiological marker, determined by spirometry; it typically occurs in the setting of noxious environmental exposures (e.g., cigarette smoke). • Components of COPD: ◦ Emphysema: Anatomically defined condition characterized by destruction of lung alveoli with air space enlargement. ◦ Chronic Bronchitis: Clinically defined condition with chronic cough and phlegm. ◦ Small Airway Disease: Condition in which small bronchioles are narrowed and reduced in number. • Clinical Context: ◦ Patients with smoking history but no airflow obstruction may still have emphysema/airway disease on CT; they have not escaped the harmful effects of smoking. ◦ Emerging concerns include vaping and inhaled cannabis, especially in adolescents. ◦ Cystic fibrosis patients share features like chronic bronchitis and emphysema but are not included in the classic definition of COPD. • Epidemiology: ◦ Global impact: ~480 million individuals currently; projected to reach 592 million by 2050. ◦ United States: Affects >15 million people; it is the fourth leading cause of death. ◦ Gender Trends: Prevalence in females now equals or exceeds that of males due to historical smoking patterns. • Special Phenotypes: ◦ PRISm (Preserved ratio–impaired spirometry): Normal FEV1/FVC but reduced FEV1; associated with increased mortality. ◦ Pre-COPD: Patients with significant CT changes (emphysema, airway wall thickening) but normal physiology (normal FEV1 and FEV1/FVC). ◦ Emphysema-predominant: Early emphysema progression through standard severity grades. ◦ Airway disease–predominant: Initial airway inflammation; FEV1 falls while maintaining a normal FEV1/FVC ratio.

2. ETIOLOGY & PATHOPHYSIOLOGY

• Anatomical Sites of Damage: ◦ Large Airways: Mucus gland enlargement and goblet cell hyperplasia → cough and mucus production (chronic bronchitis). ◦ Small Airways (≤2 mm): Primary site of increased airflow resistance; involves goblet cell metaplasia, fibrosis, and mucus accumulation. • Lung Parenchymal Destruction (Emphysema): ◦ Mechanism: Alveolar walls become perforated and obliterated → coalescence into large emphysematous air spaces. ◦ Types: ◦ Centrilobular: Associated with smoking; primarily in upper lobes. ◦ Panlobular: Associated with alpha-1 antitrypsin deficiency; predominantly in lower lobes. ◦ Paraseptal: Distributed along the pleural margins. • Pathogenesis of Emphysema (4 Interrelated Events): ◦ Event 1: Chronic exposure → inflammatory and immune cell recruitment (macrophages, neutrophils, lymphocytes). ◦ Event 2: Release of proteinases → damage to extracellular matrix, vasculature, and gas exchange surfaces. ◦ Event 3: Structural cell death → oxidant-induced damage, cellular senescence, and proteolytic loss of cellular-matrix attachments. ◦ Event 4: Disordered repair of elastin and other extracellular matrix components → air space enlargement. • Hyperinflation Dynamics: ◦ Mechanism: Increased residual volume (RV) and RV/total lung capacity ratio → increased elastic recoil pressure but flattened diaphragm. ◦ Consequences: Reduced zone of apposition, higher tension required for breathing, and impaired rib cage movement due to the thoracic cage being distended beyond its normal resting volume.

3. CLINICAL FEATURES

• Primary Symptoms: Chronic cough, sputum production, and exertional dyspnea. • Physical Examination Findings: ◦ Early Stage: Often entirely normal. ◦ Advanced Stage: Prolonged expiratory phase, expiratory wheezing, barrel chest (hyperinflation), and use of accessory muscles (tripod position). ◦ Systemic Signs: Cyanosis and cachexia (weight loss/loss of subcutaneous fat → independent poor prognostic factor). • Clinical Warning: ◦ Clubbing: NOT a sign of COPD. If present, it must be investigated for other causes such as lung cancer.

4. INVESTIGATIONS & DIAGNOSIS

  1. Spirometry (Primary Diagnostic Tool): ◦ Requirement: FEV1/FVC < 0.7 → confirms airflow obstruction. ◦ Severity Grading (GOLD Criteria): ◦ Mild: FEV1 ≥80% predicted ◦ Moderate: FEV1 50-79% predicted ◦ Severe: FEV1 30-49% predicted ◦ Very severe: FEV1 <30% predicted ◦ Severity Grading (ATS/ERS Criteria): ◦ Mild: zFEV1 > -1.645 ◦ Moderate: zFEV1 between -2.51 and -4 ◦ Severe: zFEV1 < -4
  2. Imaging (Chest CT): ◦ Identification of emphysema patterns (Centrilobular, Panlobular, Paraseptal). ◦ Detection of mucus plugs → associated with increased mortality risk.
  3. Genetic Testing: ◦ Serum alpha-1 antitrypsin levels to identify high-risk PiZ genotypes.
  4. Risk Factor Assessment: ◦ Calculation of pack-years (packs/day imes years) as a predictor for FEV1 decline. ◦ Identification of environmental exposures (dust, fumes, etc.) and history of childhood respiratory illnesses.

5. MANAGEMENT & TREATMENT

  1. Non-Pharmacologic Therapy: • Smoking Cessation: Most effective intervention to slow lung function decline. • Oxygen Therapy: Indicated for patients with hypoxemia. • Lung Volume Reduction Surgery: For specific cases of emphysema.
  2. Pharmacologic Therapy (Symptom Management - Dyspnea): • Step 1: Initial monotherapy (LABA or LAMA). • Step 2: If symptoms persist → Combination therapy (LABA + LAMA).
  3. Pharmacologic Therapy (Exacerbation Reduction): • Initial Step: LABA or LAMA. • Decision Pathway based on Blood Eosinophils (eos): ◦ If blood eos < 300 → LABA + LAMA. ◦ If blood eos ≥ 300 → LABA + LAMA + ICS.
  4. Targeted Add-on Therapies: • Rotflumilast: Indicated for patients with FEV1 < 50% and chronic bronchitis. • Azithromycin: Preferred for former smokers. • Dupilumab: Used for chronic bronchitis.

6. PROGNOSIS & COMPLICATIONS

• Prognostic Factors: ◦ Reduced FEV1 levels. ◦ Presence of emphysema. ◦ Frequency of exacerbations (higher frequency → more lung function loss). ◦ Cachexia (independent poor prognostic factor). • Complications: ◦ Cor Pulmonale: Result of pulmonary hypertension; less common with oxygen therapy. ◦ Lung Cancer: Increased risk in patients with significant smoking history.

7. KEY PEARLS & CLINICAL TRAPS

• Clinical Trap: Clubbing is NOT a sign of COPD; its presence warrants investigation for lung cancer. • Key Distinction: FEV1/FVC < 0.7 is the definitive threshold for airflow obstruction. • Management Logic: Use blood eosinophil counts as a biomarker to determine the addition of Inhaled Corticosteroids (ICS) in the exacerbation reduction pathway. • Risk Factor: Alpha-1 antitrypsin deficiency (PiZ) is a known genetic driver of early-onset disease.

Reference Tables

TABLE 303-1 Comparison of GOLD and ATS/ERS Criteria for Severity of Airflow Obstruction SEVERITY Mild Moderate Severe…

Harrison's 22e, p.2255

GOLD ERS/ATS
SEVERITY SPIROMETRY SEVERITY SPIROMETRY
Mild FEV/FVC <0.7 and FEV ≥80% predicted
1 1		 a FEV/FVC –1.645
1 1
FEV/FVC <0.7 and FEV ≥50% but <80% predicted
1 1		 Mild
Severe FEV/FVC <0.7 and FEV ≥30% but <50% predicted
1 1		 Moderate FEV/FVC <LLN and zFEV between –2.51 and –4
1 1
FEV/FVC <0.7 and FEV <30% predicted
1 1		 Severe